Literature DB >> 34007697

Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System.

Megan Olander1, Stephen Waring2, David D Stenehjem1, Allise Taran2, Paul Ranelli1, Jacob T Brown1.   

Abstract

BACKGROUND: Considerable progress has been made in the way of pharmacogenetic research and the development of clinical recommendations; however, its implementation into clinical practice has been slower than anticipated. We sought to better understand its lack of clinical uptake within primary care. AIM: The primary objective of this survey was to ascertain primary care clinicians' perceptions of pharmacogenetic use and implementation in an integrated health system of metropolitan and rural settings across several states.
METHODS: Primary care clinicians (including MDs, DOs, NPs, and PAs) were invited to participate in a survey via email. Questions about pharmacogenetics knowledge and perceptions were presented to assess current understanding and usage of pharmacogenetics in practice.
RESULTS: The rate of response for the survey was 17%. Of the 90 respondents, 58% were female, 69% were MDs/DOs, 20% were NPs, and 11% were PAs. Fifty-eight percent of respondents received their clinical degree in or after 2000. Ninety percent of respondents noted that they were uncomfortable ordering a pharmacogenetics test, with 76% stating they were uncomfortable applying the results of a pharmacogenetic test. Notably, 78% of respondents were interested in having pharmacogenetic testing available through Medication Therapy Management (MTM) services, although PAs were significantly less interested as compared to NPs and MD/DOs. Ninety-five percent of respondents were interested in a clinical decision support tool relevant to pharmacogenetic results.
CONCLUSIONS: As a whole, prescribing clinicians in primary care clinics are uncomfortable in the ordering, interpreting, and applying pharmacogenetic results to individual patients. However, favorable attitudes towards providing pharmacogenetic testing through existing MTM clinics provides the opportunity for pharmacists to advance existing practices. © University of Minnesota Libraries Publishing.

Entities:  

Keywords:  pharmacogenetics; provider survey

Year:  2018        PMID: 34007697      PMCID: PMC6438554          DOI: 10.24926/iip.v9i2.970

Source DB:  PubMed          Journal:  Innov Pharm        ISSN: 2155-0417


  12 in total

Review 1.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

2.  Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.

Authors:  E J Stanek; C L Sanders; K A Johansen Taber; M Khalid; A Patel; R R Verbrugge; B C Agatep; R E Aubert; R S Epstein; F W Frueh
Journal:  Clin Pharmacol Ther       Date:  2012-01-25       Impact factor: 6.875

3.  ASHP statement on the pharmacist's role in clinical pharmacogenomics.

Authors: 
Journal:  Am J Health Syst Pharm       Date:  2015-04-01       Impact factor: 2.637

Review 4.  Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.

Authors:  P J Caraballo; S J Bielinski; J L St Sauver; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

5.  Patient care services in rural Minnesota community pharmacies.

Authors:  Jordan D Haag; Timothy P Stratton
Journal:  J Am Pharm Assoc (2003)       Date:  2010 Jul-Aug

Review 6.  Clinical decision support for genetically guided personalized medicine: a systematic review.

Authors:  Brandon M Welch; Kensaku Kawamoto
Journal:  J Am Med Inform Assoc       Date:  2012-08-25       Impact factor: 4.497

7.  Redefining the role of the pharmacist: medication therapy management.

Authors:  Peter Hilsenrath; Joseph Woelfel; Allen Shek; Katrina Ordanza
Journal:  J Rural Health       Date:  2012-05-31       Impact factor: 4.333

8.  Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas.

Authors:  Elizabeth H Dorfman; Susan Brown Trinidad; Chelsea T Morales; Kevin Howlett; Wylie Burke; Erica L Woodahl
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

Review 9.  Collaborative Counseling Considerations for Pharmacogenomic Tests.

Authors:  Heather A Zierhut; Colleen A Campbell; Allison G Mitchell; Amy A Lemke; Rachel Mills; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2017-08-07       Impact factor: 4.705

10.  Perceptions of interprofessional collaboration of general practitioners and community pharmacists - a qualitative study.

Authors:  Christin Löffler; Carolin Koudmani; Femke Böhmer; Susanne D Paschka; Jennifer Höck; Eva Drewelow; Martin Stremme; Bernd Stahlhacke; Attila Altiner
Journal:  BMC Health Serv Res       Date:  2017-03-21       Impact factor: 2.655

View more
  2 in total

1.  Ensuring equity: Pharmacogenetic implementation in rural and tribal communities.

Authors:  Tianna M Leitch; Shayna R Killam; Karen E Brown; Kirk C Katseanes; Kathleen M George; Corbin Schwanke; Joshua Loveland; Abdallah F Elias; Kerry Haney; Kate Krebsbach; LeeAnna I Muzquiz; Susan B Trinidad; Erica L Woodahl
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

2.  Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management.

Authors:  Thomas M Schneider; Michael T Eadon; Rhonda M Cooper-DeHoff; Kerri L Cavanaugh; Khoa A Nguyen; Meghan J Arwood; Emma M Tillman; Victoria M Pratt; Paul R Dexter; Allison B McCoy; Lori A Orlando; Stuart A Scott; Girish N Nadkarni; Carol R Horowitz; Joseph L Kannry
Journal:  J Pers Med       Date:  2021-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.